Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis

Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis

BackgroundAnthracyclines are widely used paediatric chemotherapy drugs, but anthracycline-induced cardiotoxicity (ACT) can cause heart failure in 16% of children. Previous studies have linked genetic variants to ACT and proposed pharmacogenomic testing for anthracycline-treated children; however, th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ling Yin Fritz Wong, Alastair G. Sutcliffe, Carmen Lok Tung Ho, Yan Lu, Carrie L. Williams, Faiza Afzal, Mitana Purkayastha
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	pharmacogenomics polymorphism anthracycline chemotherapy cardiotoxicity childhood cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1568320/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)

Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)

Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)

MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
by: E. V. Grakova, et al.
Published: (2023-01-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review
by: Xiao S, et al.
Published: (2025-07-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01)

Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials
by: Siyu Li, et al.
Published: (2025-07-01)

Combined Utility of Speckle Tracking Echocardiography and Cardiac Biomarkers for Early Detection of Anthracycline-Induced Cardiotoxicity in Pediatric Oncology Patients
by: Cristiana Stolojanu, et al.
Published: (2024-12-01)

Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy
by: Stephanie Itala Rizk, et al.
Published: (2025-05-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Evaluation of left atrial strain changes in patients with breast cancer after anthracycline therapy
by: Mostafa El Mokadem, et al.
Published: (2025-05-01)

Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
by: Rizkyastari Onny, et al.
Published: (2025-06-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Treatment of cardiotoxicity in patients with invasive breast cancer during neoadjuvant chemotherapy
by: Grigorii A. Ignatenko, et al.
Published: (2024-09-01)

Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
by: Jessica T. Li, et al.
Published: (2024-06-01)

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity
by: V. D. Levina, et al.
Published: (2022-12-01)

Utility of global longitudinal strain in early identification of chronic cardiotoxicity in asymptomatic long-term malignant lymphoma survivors with normal left ventricle ejection fraction
by: Eva Rihackova, et al.
Published: (2025-03-01)

Age‐Related Long‐Term Longitudinal Changes in Left Ventricular Mechanical Function in Breast Cancer Patients Undergoing Anthracycline and Trastuzumab Treatment
by: Begimai Akbalaeva, et al.
Published: (2025-04-01)

Dynamics of SERPINA3 in response to anthracycline treatment and cardiovascular dysfunction
by: Hanne M. Boen, et al.
Published: (2025-03-01)

Natural strategies of preventing anthracycline-induced cardiotoxicity – a review
by: Anca STOICA, et al.
Published: (2022-12-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines
by: Iokfai Cheang, et al.
Published: (2025-06-01)

Cardiotoxicity in Children With Acute Ieukemia Treated by Anthracycline; Detected by Cardiac Troponins and Echcocardiography
by: Yaran Abbas Abdulqader, et al.
Published: (2023-04-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01)

Cardiotoxicity in breast cancer – Are we getting to the heart of the matter?
by: Zine Steenkamp, et al.
Published: (2024-11-01)